Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12366305 | 0.87 | LMNA (0.36) | POLBALDH1A1SMN1; SMN2KDM4EGAA | |
| SCHEMBL18121607 | 0.86 | POLB (0.40) | POLBALDH1A1SMN1; SMN2KDM4EGAA | |
| SCHEMBL21961825 | 0.86 | POLB (0.40) | POLBALDH1A1SMN1; SMN2KDM4EGAA | |
| SCHEMBL21948333 | 0.86 | POLB (0.40) | POLBALDH1A1SMN1; SMN2KDM4EGAA | |
| SCHEMBL3363728 | 0.82 | GPR119 (0.38) | ALDH1A1LMNAMAPK1GPR119KMT2A | |
| SCHEMBL3309558 | 0.81 | MAPK1 (0.38) | POLBALDH1A1SMN1; SMN2HPGDLMNA | |
| SCHEMBL8516141 | 0.78 | GPR119 (0.32) | LMNAMAPK1GPR119 | |
| SCHEMBL12401055 | 0.77 | GPR119 (0.35) | LMNAMAPK1GPR119 | |
| SCHEMBL7056630 | 0.77 | INPP5A (0.40) | POLBALDH1A1SMN1; SMN2GAAHPGD | |
| SCHEMBL1134398 | 0.77 | GPR119 (0.33) | POLBALDH1A1KDM4ELMNAMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11834450-B2 | Compounds having ((3-nitrophenyl)sulfonyl)acetamide as BCL-2 inhibitors | Eil Therapeutics, Inc. (US) | 2023-12-05 | — | — | US | disclosed |
| US-20230173078-A1 | SMARCA DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-06-08 | — | — | US | disclosed |
| US-11661437-B2 | Steroid derivative regulators, method for preparing the same, and uses thereof | JIANGSU HANSOH PHARMACEUTICAL GROUP CO., LTD. (CN) | 2023-05-30 | — | — | US | disclosed |
| US-20220017565-A1 | STEROID DERIVATIVE REGULATORS, METHOD FOR PREPARING THE SAME, AND USES THEREOF | SHANGHAI HANSOH BIOMEDICAL CO., LTD. (CN) | 2022-01-20 | — | — | US | disclosed |
| EP-1921077-B1 | AGENT FOR TREATING AND/OR PREVENTING SLEEP DISORDER | KYOWA HAKKO KIRIN CO LTD (JP) | 2017-07-26 | — | — | EP | disclosed |
| EP-3002283-B1 | THIAZOLE DERIVATIVES | KYOWA HAKKO KIRIN CO LTD (JP) | 2017-06-14 | — | — | EP | disclosed |
| US-9562033-B2 | Inhibitors of viral replication, their process of preparation and their therapeutical uses | LABORATOIRE BIODIM (FR) | 2017-02-07 | — | — | US | disclosed |
| US-20160039783-A1 | Inhibitors of Viral Replication, Their Process of Preparation and Their Therapeutical Uses | HIVIH (FR) | 2016-02-11 | — | — | US | disclosed |
| US-8907128-B2 | Boron compound with amino acid skeleton containing cyclo ring-type ring | STELLA PHARMA CORPORATION (JP) | 2014-12-09 | — | — | US | disclosed |
| US-20130225861-A1 | Boron Compound With Amino Acid Skeleton Containing Cyclo Ring | STELLA PHARMA CORPORATION (JP) | 2013-08-29 | — | — | US | disclosed |
| US-20090105482-A1 | Urea Glucokinase Activators | NOVO NORDISK A/S (DK) | 2009-04-23 | — | — | US | disclosed |
| US-7511144-B2 | Reverse hydroxamic acid derivatives | KAKEN PHARMACEUTICAL CO., LTD. (JP) | 2009-03-31 | — | — | US | disclosed |
| US-7511144-B2 | Reverse hydroxamic acid derivatives | KAKEN PHARMACEUTICAL CO., LTD. (JP) | 2009-03-31 | — | — | US | disclosed |
| US-20090082463-A1 | N-substituted phenylacetamide derivative and pharmaceutical composition containing the same | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2009-03-26 | — | — | US | disclosed |
| EP-1431285-B1 | REVERSE HYDROXAMIC ACID DERIVATIVES | KAKEN PHARMA CO LTD (JP) | 2009-01-07 | — | — | EP | disclosed |
| WO-2008106139-A1 | INHIBITORS OF SERINE PROTEASES FOR THE TREATMENT OF HCV INFECTIONS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2008-09-04 | — | — | WO | disclosed |
| US-7345077-B2 | 4-(substituted cycloalkylmethyl) imidazole-2-thiones, 4-(substituted cycloalkenylmethyl) imidazole-2-thiones, 4- (substituted cycloalkylmethyl) imidazol-2-ones and 4- (substituted cycloalkenylmethyl) imidazol-2-ones and related compounds | ALLERGAN, INC. (US) | 2008-03-18 | — | — | US | disclosed |
| US-20070213361-A1 | Preventive and/or therapeutic agent for neutrophilic inflammatory diseases | KYOWA KIRIN CO., LTD. (JP) | 2007-09-13 | — | — | US | disclosed |
| US-20070213361-A1 | Preventive and/or therapeutic agent for neutrophilic inflammatory diseases | KYOWA KIRIN CO., LTD. (JP) | 2007-09-13 | — | — | US | disclosed |
| US-20070179167-A1 | Inhibitors of serine proteases | VERTEX PHARMACEUTICALS INCORPORATED | 2007-08-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11834450-B2 | Compounds having ((3-nitrophenyl)sulfonyl)acetamide as BCL-2 inhibitors | BCL2, BCL2A1, BCL2L1 | POLB 2006/4885ALDH1A1 722/4885SMN1; SMN2 1143/4885 |
| US-20130225861-A1 | Boron Compound With Amino Acid Skeleton Containing Cyclo Ring | BCAT1, BCAT2, SLC1A5 | POLB 3059/4885ALDH1A1 4739/4885SMN1; SMN2 1642/4885 |
| US-11661437-B2 | Steroid derivative regulators, method for preparing the same, and uses thereof | GABRR1, GABRB1, GABRD | POLB 2487/4885ALDH1A1 1040/4885SMN1; SMN2 1628/4885 |
| US-20090082463-A1 | N-substituted phenylacetamide derivative and pharmaceutical composition containing the same | HRH4, HRH2, CNR2 | POLB 3581/4885ALDH1A1 321/4885SMN1; SMN2 1880/4885 |
| US-20090105482-A1 | Urea Glucokinase Activators | GCK, GCKR, HK2 | POLB 2990/4885ALDH1A1 1040/4885SMN1; SMN2 2536/4885 |
| US-20070179167-A1 | Inhibitors of serine proteases | PRSS1, PRSS3, PRSS2 | POLB 3945/4885ALDH1A1 1374/4885SMN1; SMN2 2265/4885 |
| US-20230173078-A1 | SMARCA DEGRADERS AND USES THEREOF | SMARCA1, SMARCA2, SMARCC2 | POLB 22/4885ALDH1A1 2230/4885SMN1; SMN2 716/4885 |
| US-20160039783-A1 | Inhibitors of Viral Replication, Their Process of Preparation and Their Therapeutical Uses | POLRMT, MAVS, EIF2AK2 | POLB 12/4885ALDH1A1 4105/4885SMN1; SMN2 3115/4885 |
| US-20070213361-A1 | Preventive and/or therapeutic agent for neutrophilic inflammatory diseases | MPO, MSR1, NR4A3 | POLB 3762/4885ALDH1A1 873/4885SMN1; SMN2 4264/4885 |
| US-20220017565-A1 | STEROID DERIVATIVE REGULATORS, METHOD FOR PREPARING THE SAME, AND USES THEREOF | GABRR1, GABRB1, GABRD | POLB 2487/4885ALDH1A1 1040/4885SMN1; SMN2 1628/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.